About
Benoit P. Bouche joined Ampersand as an Operating Partner in 2022 and chairs the board of P95. His career spans nearly 40 years in healthcare businesses as an entrepreneur, investor, advisor, and board member, with a focus on the pharmaceutical outsourcing industry. He was previously President and CEO of Nexelis, an immunology-focused lab and former Ampersand portfolio company acquired by IQVIA, and holds a PharmD (1984) and a Ph.D. in Pharmaceutical Sciences/Biotechnology (1986), along with completion of Harvard Business School's Advanced Management Program (2002).
Invests in
BiotechHealthtech
Investments
Board seats
P95
Per the firm's website.
Colleagues at Ampersand
Aditya V. Goel
Associate at Ampersand
Cole S. Aldrich
Senior Associate at Ampersand
David Q. Anderson
General Partner at Ampersand
Dean D. Schauer
Operating Partner at Ampersand
Elias J. Laimboeck
Senior Associate at Ampersand
Emanuele M. Delfino
Associate at Ampersand
Eric B. Lev
General Partner at Ampersand
Frank R. Witney
Operating Partner at Ampersand
Frequently asked questions
- Who is Benoit P. Bouche?
- Benoit P. Bouche joined Ampersand as an Operating Partner in 2022 and chairs the board of P95. His career spans nearly 40 years in healthcare businesses as an entrepreneur, investor, advisor, and board member, with a focus on the pharmaceutical outsourcing industry. He was previously President and CEO of Nexelis, an immunology-focused lab and former Ampersand portfolio company acquired by IQVIA, and holds a PharmD (1984) and a Ph.D. in Pharmaceutical Sciences/Biotechnology (1986), along with completion of Harvard Business School's Advanced Management Program (2002).
- Where does Benoit P. Bouche work?
- Benoit P. Bouche is Operating Partner at Ampersand.
- What does Benoit P. Bouche invest in?
- Benoit P. Bouche invests in Biotech, Healthtech.
- What boards does Benoit P. Bouche sit on?
- Benoit P. Bouche holds tracked board seats at P95.